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1. Introduction 
Plasma LDL-C level is the most well established risk factor for coronary heart disease (CHD) 
(1). Accordingly, the numerous studies have shown that the LDL-C lowering drugs, statins 
significantly reduced plasma LDL-C together with approximately 30% reduction in 
cardiovascular events (2). Therefore, it has been generally believed that the cardiovascular 
events are directly associated with the elevated LDL-C or its modified oxidized LDL (3). In 
this manuscript, we have reviewed the patho-physiological role of LDL-C and remnant 
lipoproteins at cardiovascular events in Japanese sudden cardiac death (SCD) cases (Table 
1), especially in SCD cases with nearly normal coronary arteries (coronary atherosclerosis 
grade (-) and (±), namely Pokkuri Death Syndrome (PDS). As the formation and 
physiological role of LDL in liver and plasma has been well established, those of remnant 
lipoproteins (RLP) have also been established recently as a risk for CHD (4-6). As shown in 
Figure 1, TG-rich lipoprotein (TRL) remnants are formed in the circulation when apoB-48 
containing chylomicrons (CM) of intestinal origin or apoB-100 containing VLDL of hepatic 
origin are converted by lipoprotein lipase (and to a lesser extent by hepatic lipase) into 
smaller and denser particles of LDL. Compared with their nascent precursors, TRL 
remnants are depleted of triglycerides, phospholipids, apoA-I and apoA-IV in the case of 
CM and are enriched in cholesteryl esters, apoCs and apoE (6). They can thus be identified, 
separated, or quantified in plasma on the basis of their density, charge, size, specific lipid 
components, apolipoprotein composition and apolipoprotein immunospecificity. This 
should mean that we have now two identified cardiovascular risk factors, LDL and RLP 
(CM remnants and VLDL remnants) (Figure 1), in SCD and PDS cases and attempted to 
understand the differences in their contributions to CHD.  
Recent evidences have suggested that elevated plasma levels of remnant lipoprotein –
cholesterol (RLP-C) and reduced lipoprotein lipase (LPL) activity relate to the promotion of 
coronary artery events associated with spasm (7-9), which has been often observed as a 
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major risk of sudden cardiac death (10). Likewise, we previously reported a significant 
association between sudden cardiac death and plasma levels of RLP-C and RLP-triglyceride 
(RLP-TG), especially in cases of Pokkuri death (11). Pokkuri death in Japanese refers the 
cases who “die suddenly and unexpectedly”, and had not taken any medications prior to 
death. PDS has been categorized as one type of SCD syndrome, but not having coronary 
atherosclerosis and without cardiac hyperplasia. Most of such cases have been observed in 
Asian young males, and as yet, no report of PDS is seen in Caucasians. 
 
 Control (n=76) SCD (n=165) 
 mean±SD mean±SD 
 
Non-athero 
(n=49) 
Athero 
(n=27) 
P value
Non-athero 
(n=48) 
Athero 
(n=117) 
P value 
Age in years 42.7±16.5 51.3±14.5 < 0.01 37.5±13.1 54.5±10.5 < 0.0001 
Male/Female 41/8 24/3 NS 43/5 90/27 NS 
Heart weight (g) 358±86 387±80 NS 356±82 414±91 < 0.001 
Body weight (kg) 61.7±11.7 62.9±9.5 NS 65.2±11.9 63.9±12.7 NS 
Body height (cm) 165±8.2 164±9.1 NS 168±9.6 164±8.5 NS 
BMI 22.6±4.8 23.5±3.3 NS 22.9±3.5 23.8±3.7 NS 
Postmortem period 
(h) 
8.7±2.9 8.6±3.5 NS 8.9±3.3 8.2±3.4 NS 
SCD cases without atherosclerosis (Non-athero; n=48) are categorized as PDS in this manuscript. 
Table 1. Demography data of sudden cardiac death and control death cases with and 
without coronary artery atherosclerosis 
Both SCD with coronary atherosclerosis and PDS without coronary atherosclerosis showed 
abnormally high plasma RLP-C and RLP-TG level, namely postprandial remnant 
hyperlipoproteinemia in postmortem plasma (11-14) (Table 2). RLP isolated from 
postmortem plasma by an immunoaffinity gel separation method (15) showed atherogenic 
and inflammatory effects (16, 17) similar to the RLP isolated from plasma of living subjects 
(6). In particular, Shimokawa and colleagues (18) reported that RLP isolated from plasma of 
SCD cases induced strong spasm in in-vivo setting by up-regulating the Rho-kinase 
pathway in healthy porcine coronary arteries, which might mimic the etiological 
phenomenon of PDS. But LDL (or Ox-LDL) did not enhance the formation of coronary 
vascular lesions in regions where coronary spasm could be induced in the same 
experimental model (19).  
Further, Takeichi et al. (11-13) suggested RLP as one of the major risk factors in SCD and 
PDS. Although LDL-C levels were also elevated in parallel with the majority of SCD cases 
who have severe coronary atherosclerosis, the role of LDL-C in fatal clinical events was not 
fully understood in these cases. Therefore, the relationship between plasma levels of RLP-C, 
RLP-TG, LDL-C and the incidence of cardiovascular events has been studied in SCD cases 
with and without coronary atherosclerosis as well as in control death cases (Table2). In 
particular, we were interested in PDS cases among SCD cases as a disease model of coronary 
artery events which were neither associated with the severity of coronary artery 
atherosclerosis nor plaque ruptures (20).  
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Fig. 1. Metabolic map of lipoproteins. After fat intake, the intestine secretes chylomicrons 
(CM), the triglycerides of which are lipolyzed by lipoprotein lipase (LPL). The LPL reaction 
constitutes the initial process in the formation of triglyceride-rich lipoprotein (TRL) 
remnants (CM remnants and VLDL remnants) . The VLDL secretion process is partly 
regulated by the rate of FFA influx to the liver. VLDL triglycerides are lipolyzed by 
endothelial-bound lipoprotein lipase and VLDL remnant particles are formed. The final TRL 
remnant composition is modulated by the cholesterol ester transfer protein (CETP) reaction 
with HDL, hepatic lipase (HL), and the exchange of soluble apolipoproteins such as C-I, C-
II, C-III and E. The great majority of the remnants are removed from plasma by receptor-
mediated processes and the principal receptors are the LDL receptor and the LDL-receptor-
related protein (LRP) in liver. It is probable that the CM remnants use both of these routes, 
whereas the VLDL remnants are more likely to use only the LDL receptor. 
 
 Control (n = 76) SCD(n = 165)  
 
 
median 25-75% tile median 25-75% tile P valuea 
Total cholesterol 
(mg/dl) 
177 134-209 211 175-243 < 0.0001 
Triglyceride 
(mg/dl) 
116 81-157 148 100-230 < 0.001 
VLDL-C (mg/dl) 20.3 6.0-35.6 27.0 16.1-47.6 < 0.001 
LDL-C (mg/dl) 92 67-132 134 99-167 < 0.0001 
HDL-C (mg/dl) 42 31-60 41 33-53 NS 
RLP-C (mg/dl) 9.1 5.4-13.8 16.4 10.0-26.9 < 0.001 
RLP-TG (mg/dl) 49 33-78 81 51-132 < 0.001 
Table 2(a). Plasma lipid and lipoprotein levels in total cases of sudden cardiac death (SCD) 
and control death. 
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 Control (n = 49) Pokkuri (n = 48)  
 
 
median 25-75% tile median 25-75% tile P valuea 
Total cholesterol 
(mg/dl) 
165 121-205 182 149-221 < 0.01 
Triglyceride 
(mg/dl) 
114 75-129 120 96-216 < 0.005 
VLDL-C (mg/dl) 20.3 5.1-35.2 27.0 16.2-43.7 NS 
LDL-C (mg/dl) 89 67-130 118 83-140 < 0.001 
HDL-C (mg/dl) 39 30-59 41 34-56 NS 
RLP-C (mg/dl) 7.1 5.1-10.1 14.3 9.5-26.4 < 0.001 
RLP-TG (mg/dl) 48 33-67 78 50-117 < 0.001 
Table 2(b). Plasma lipid and lipoprotein levels in cases of Pokkuri death and control death 
(without coronary artery atherosclerosis). 
 
 Control (n = 27) SCD(n = 117)  
 
 
median 25-75% tile median 25-75% tile P valuea 
Total cholesterol 
(mg/dl) 
203 171-216 219 185-248 < 0.05 
Triglyceride (mg/dl) 120 82-188 154 106-232 < 0.05 
VLDL-C (mg/dl) 21.5 7.0-39.0 26.9 15.8-49.4 NS 
LDL-C (mg/dl) 95 69-136 148 103-179 < 0.01 
HDL-C (mg/dl) 45 34-63 41 33-51 NS 
RLP-C (mg/dl) 12.5 10.1-18.5 17.2 11.4-46.8 < 0.05 
RLP-TG (mg/dl) 55 38-84 83 51-142 < 0.05 
Table 2(c). Plasma lipid and lipoprotein levels in cases of sudden cardiac death (SCD) and 
control death( with coronary artery atherosclerosis). 
We have established the cut-off values and the likelihood ratios of total cholesterol (TC), TG, 
RLP-C, RLP-TG and LDL-C in plasma of SCD and control death cases with and without 
coronary atherosclerosis after adjusting for the postmortem conditions (Table 3) (21). The 
cut-off values and likelihood ratios of these major plasma lipids and lipoproteins were 
calculated by using an ROC analysis model for predicting the risk of fatal clinical events 
with and without coronary atherosclerosis. In approximately two-third of sudden cardiac 
death cases, we found postprandial remnant hyperlipoproteinemia, especially rich in very 
low density lipoprotein (VLDL) remnants (14) and significantly elevated LDL-C. Both 
lipoproteins were significantly elevated in SCD, but LDL-C in PDS cases was within the 
normal range, together with significantly elevated remnant lipoproteins in fatal clinical 
events. Therefore, we found that PDS cases were a good disease model to distinguish the 
role of LDL and RLP as cardiovascular risk factors.  
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Cut-off 
(mg/dl)
Sensitivity
(%) 
Specificity
(%) 
PPV 
Positive predictive 
value 
NPV 
Negative 
predictive 
value 
Likelihood ratio 
 
(1) Total  
(SCD : Control) 
      
RLP-C 12.8 67.9 68.2 84.4 45.7 2.12 
RLP-TG 53.3 72.9 60.8 82.5 46.9 1.86 
LDL-C 92.5 79.4 52.7 81.0 50.2 1.68 
Total Cholesterol 181 69.3 49.3 77.6 38.7 1.37 
Triglycerides 117 66.3 49.3 76.8 36.6 1.31 
       
(2) Non-athero  
(Pokkuri: Control) 
      
RLP-C 10.1 70.2 77.5 75.4 72.7 3.13 
RLP-TG 67 66.7 75.6 72.8 62.9 2.73 
LDL-C 106 58.3 61.7 59.9 60.2 1.52 
Total Cholesterol 165 63.8 51.1 56.1 59.0 1.30 
Triglycerides 113 53.3 50.0 51.1 52.2 1.07 
       
(3) Athero  
(SCD : Control) 
      
RLP-C 13.4 65.3 69.2 90.2 31.5 2.12 
RLP-TG 79.4 52.5 72.4 89.2 26.0 1.90 
LDL-C 102 79.7 57.1 89.0 39.4 1.86 
Total Cholesterol 217 55.2 78.6 91.8 28.8 2.58 
Triglycerides 131 64.9 64.3 88.7 29.7 1.82 
Number of cases are as follows: (1) total SCD; SCD (n=165) and Control (n=76) : (2) Non-athero; Pokkuri 
(Non-athero SCD) (n=48) and Non-athero control (n=49): (3) Athero; Athero SCD (n=117) and Athero-
control (n=27). 
Table 3. Cut-off value of RLP-C and RLP-TG from ROC analysis in predicting sudden 
cardiac death 
2. Role of plasma LDL and remnant lipoproteins at coronary atherosclerosis 
and cardiovascular events 
Based on our autopsy studies, more than two thirds of SCD cases were found to be 
associated with postprandial remnant hyperlipoproteinemia [11-15]. If severe spasm of the 
coronary artery is to be a crucial event prior to cardiac death in PDS, we may say that the 
vasospasm is not very likely to occur in coronary arteries with severe coronary artery 
atherosclerotic lesions due to reduced elasticity and increased stiffness or hardness of the 
vascular wall. Caucasians experience more severe coronary atherosclerosis than Japanese or 
other Southeastern Asians. Accordingly, this might be one explanation why PDS is 
uncommon among Caucasians. In view of this background, PDS could be an interesting 
disease case to study coronary heart disease (CHD), which is independent of severity of 
coronary atherosclerosis and plaque ruptures in spite of remnant hyperlipoproteinemia. 
Significantly younger age of PDS cases compared to the other SCD cases may be one of the 
reasons why PDS cases were not associated with severe coronary atherosclerosis. The 
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prevalence of severe coronary atherosclerosis is known to be strongly associated with age 
(Table1). We found that plasma lipid (TC, TG) and lipoprotein (LDL-C, RLP-C, and RLP-TG) 
levels were significantly elevated in these sudden cardiac death cases as compared with 
those in control death cases when coronary atherosclerosis was pathologically graded above 
(1+), reflecting the clinical feature of severe coronary atherosclerosis (11-13). Most of the 
coronary arteries in PDS cases were pathologically graded as (−) and (±), indicating no 
coronary atherosclerosis [11]. Plasma LDL-C in SCD cases was shown to be correlated with 
the severity of coronary artery atherosclerosis [13]. This is in line with the perception (albeit 
by implication) that LDL-C plays a major role in the progression of coronary atherosclerosis 
in CHD patients. We found that the incidence of elevated plasma LDL-C was significantly 
greater in SCD cases with coronary atherosclerosis compared with than in controls and PDS 
cases. However, plasma LDL-C levels were all within normal range in PDS cases (22). 
Hence, LDL-C did not seem to play a significant role at cardiovascular events in PDS, 
despite being elevated within normal range , rather the data strongly indicated an 
association between plasma LDL-C and the progression of coronary atherosclerosis in SCD 
cases.  
Elevated plasma remnant lipoproteins (RLP) levels were the most striking observation in 
PDS (RLP-C likelihood ratio; 3.13, RLP-TG; 2.73, LDL-C; 1.52, TC; 1.30, TG; 1.07) for 
predicting sudden cardiac death (Table 3). Despite the high plasma concentration of RLPs in 
PDS cases, the progression of atherosclerosis at coronary arteries was not observed. It might 
be valid to say that increased plasma RLPs may initiate the vascular endothelial damage and 
this is followed by an influx of large amounts of LDL into the vascular wall. Then it follows 
to form an advanced atherosclerotic lesion with macrophages and smooth muscle cells as 
Nakajima et al reviewed previously (6, 23). PDS cases may be in the early stage of 
atherosclerosis, which can lead cardiovascular events under certain conditions such as with 
severe stress without strong morphological changes. Therefore, the authors proposed that 
the occurrence of cardiovascular events at coronary arteries and the severity of 
atherosclerotic lesions in CHD should be considered as separate factors. Therefore, the 
intervention should be targeted to suppress the cardiovascular events more aggressively 
than to slow down the progression of atherosclerosis. Takeichi and Fujita did not observe 
frequent plaque ruptures in coronary arteries at autopsy in Japanese SCD cases [24].  
The literature on atherosclerosis has long been dominated by data in Caucasian patients 
who in most cases had severe atherosclerosis at the time of fatal clinical events. Hence, fatal 
clinical events have been believed to occur in relation to the severity of atherosclerosis in 
coronary arteries. In contrast, fatal clinical events of PDS cases had occurred in the absence 
of coronary atherosclerosis or plaque rupture. Plasma LDL-C levels were also within normal 
range associated with no coronary atherosclerosis in PDS cases. This again puts more weight 
on RLP as the causative factor of cardiovascular events. Interestingly, we found that RLP-TG 
(TG concentration in remnant lipoproteins) was not an indicator for predicting the presence 
or progression of coronary atherosclerosis even in SCD [22]; however, it was significantly 
associated with fatal clinical events in SCD including PDS (Table 2). The bioactive 
components co-localized with triglycerides in RLP such as oxidized phospholipids or their 
metabolites [25] may enhance the formation of coronary vascular lesions and may induce 
severe spasm in coronary arteries. These results also suggested that triglycerides in RLP 
were not associated with the progression of atherosclerotic plaques, but cholesterol in RLP 
was strongly associated with the severity of atherosclerosis [13, 22]. Therefore RLP-TG could 
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be an appropriate diagnostic marker for predicting cardiovascular events but not the 
severity of coronary atherosclerosis, whereas RLP-C could be a marker for predicting both 
cardiovascular events and the severity of coronary atherosclerosis. LDL-C could be a marker 
for predicting the severity of coronary atherosclerosis, but not cardiovascular events. 
Elevated Oxidized LDL seems to be associated with the presence of vulnerable plaque at 
blood vessels (6), not a causative factor for the formation or initiation of atherosclerosis 
because of it low concentration in plasma. 
3. Postprandial remnant hyperlipoproteinemia as a risk for sudden cardiac 
death 
Several clinical studies have shown that elevated plasma TG levels greatly increase the risk 
of sudden cardiac death. Results from the Paris Prospective Study (26) and The 
Apolipoprotein Related Mortality Risk Study (AMORIS) in Sweden (27) demonstrated that 
increased TG was a strong risk factor for fatal myocardial infarction. However, plasma TG 
levels can alter very easily within a short time. Therefore it has been difficult to identify the 
clinical events of elevated TG in the long term prospective studies until recently (28-30). 
If the lipid and lipoprotein levels in postmortem plasma correctly reflected the antemortem 
levels, these data could probably provide the same values with the results obtained from the 
prospective studies, which require long-term observation for evaluation. The plasma levels 
of lipids and lipoproteins in sudden death cases may reflect the feature at the moment of 
fatal clinical events followed by certain inevitable postmortem alterations, but still may 
reflect the physiological conditions when the cardiac events had occurred. Therefore, we 
analyzed postmortem plasma under well-controlled conditions to clarify the cause of 
sudden cardiac death. Plasma RLP-C and RLP-TG levels vary greatly within a short time as 
the TG levels, compared with other stable plasma markers such as HDL-C and LDL-C. 
Hence, we believe that the cross-sectional study of RLPs at the moment of sudden death is a 
superior analytical method than a prospective study of RLP (31) to identify potential risks of 
CHD. During the investigations of sudden death cases, we found that the postmortem 
alterations of lipids and lipoproteins in plasma were unexpectedly slight (21) compared 
with proteins or other bio-markers. Moreover, these plasma lipoprotein levels were very 
similar to those determined in living patients from the studies in our laboratory.  
Remnant lipoproteins are known to increase postprandially as chylomicron (CM) remnants, 
but very low density lipoprotein (VLDL) remnants also increase at the same time. The 
remarkable close correlation between the increment in the concentration of TG-rich 
lipoprotein (TRL) apoB-48 (CM) and apoB-100 (VLDL) after a fat meal indicates that 
reduced efficiency of CM particle clearance is closely coupled to the accumulation of VLDL 
particles as proposed by Karpe et al (32). Delayed clearance of CM particles, as evidently 
occurs in many hypertriglyceridemic states, may thus contribute to the elevation of apoB-
100 in TRL. More than two thirds of the SCD including PDS case observed in this study 
showed stomach full, indicating the strong association with postprandial remnant 
hyperlipoproteinemia. Significant remnant hyperlipoproteinemia was observed in the 
plasma of SCD cases compared with the control death cases.  
The postprandial increase of apoB-48-carrying CM and CM remnants after fat load is known 
to correlate well with the increase of RLP-C and RLP-TG (33). These data suggested the 
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possibility that increased RLP in the postprandial state may be mainly composed of CM 
remnants. However, unexpectedly, we found no significant differences of apoB-48 levels in 
plasma or RLP apoB-48, but found significant differences of RLP aoB-100 levels between 
SCD and control death cases (14). As previously reported by Schneeman et al. (34), 
postprandial responses (after fat load) of apoB-48 and apoB-100 were highly correlated with 
those of TRL triglycerides. Although the increase in apoB-48 represented a 3.5-fold 
difference in concentration as compared with a 1.6-fold increase in apoB-100, apoB-100 
accounted for about 80% of the increase in lipoprotein particles in TRL. Our results on 
plasma evaluation in SCD cases were very similar to the results reported by Schneeman et al 
(34). RLP apoB-100 levels were significantly elevated in SCD cases in the postprandial state 
(when RLP-C and RLP-TG were significantly elevated), however, plasma apoB-48 or RLP 
apoB-48 was not significantly elevated (14). These results strongly suggested that the major 
subset of RLP associated with fatal clinical events was apoB-100 carrying particles, but not 
apoB-48 particles.  
The absolute amount of apoB-100 in RLP is much greater than that of apoB-48 in RLP. 
Hence, VLDL remnants, endogenous lipoprotein remnants, generated in the liver, may be 
more closely associated with the risk of sudden cardiac death than exogenous CM remnants, 
irrespective of the severity of coronary atherosclerosis. Furthermore, we often found SCD 
cases that had consumed alcohol on a full stomach. It is known that alcohol increases fatty 
acids in the liver and enhances VLDL production, and inhibit LPL activity (35). Alcohol 
intake with a fatty meal is known to greatly enhance TG increase in the postprandial state. 
The intake of alcohol together with a fatty meal may easily enhance the production of apoB-
100 carrying VLDL in the liver, and increase VLDL remnants by inhibiting LPL activity and 
increase the potential risk of coronary artery in SCD cases. 
4. Comparative reactivity of LDL and remnant lipoproteins to LDL receptor in 
liver 
Clinical trials have shown that improvements in plasma LDL-C levels are associated with 
retardation of atherosclerosis and reduction in coronary artery morbidity and mortality [2, 36]. 
The major mechanism of statin therapeutic effect has been recognized as the increase of LDL 
receptor in liver to remove an elevated LDL-C in plasma. However, remnant lipoproteins have 
been also implicated in progression of atherosclerosis [37-40], with elevated remnant 
lipoprotein levels shown to independently predict clinical events in coronary artery disease 
(CAD) patients (4]. The direct comparison of reactivity between remnant lipoproteins and LDL 
to LDL receptor in liver has not been studied enough until recently. 
Major target for remnant lipoprotein research has been focused on postprandial 
dyslipidemia. Postprandial dyslipidemia has been found to be associated with endothelial 
dysfunction [42, 43] an early indicator of atherogenesis. Previous studies have shown that 
normolipidemic patients with coronary disease have elevated postprandial levels of 
triglyceride-rich lipoproteins (TRLs) and their remnants compared with healthy control 
subjects [44-49]. Elevated remnant lipoprotein levels have also been associated with 
coronary endothelial dysfunction [50], with remnants shown to stimulate expression of 
proatherothrombotic molecules in endothelial cells [51]. Therefore, the prevention and 
treatment of atherosclerosis merits pharmacotherapy targeted at regulating postprandial 
dyslipidemia, namely remnant lipoproteins beyond LDL-C [52]. Postprandial remnant 
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lipoproteins are the atherogenic lipoproteins which appear and increase postprandially into 
plasma at the initial step of lipoprotein metabolism after food intake and then change to 
further metabolized lipoproteins, such as LDL particles (Figure 1). The postprandial state 
with increased remnant lipoproteins in plasma continues almost whole day except in the 
early morning (6), while not the case in LDL. Therefore, if postprandial lipoproteins are 
atherogenic risks as Zilversmit proposed (53), those should be the primary therapeutic 
target to prevent cardiovascular disease. Increased LDL is not directly associated with the 
daily food intake as remnant lipoproteins. 
Possible mechanisms suggested for abnormal accumulation of lipoproteins postprandially 
in plasma are defective clearance in liver via receptor-mediated pathways and/or increased 
competition for high-affinity processes because of increased numbers of intestinally and 
hepatically derived particles in the postprandial state [32]. HMG-CoA reductase inhibitors 
decrease cellular cholesterol synthesis and consequently reduce the hepatic production of 
very-low-density lipoproteins (VLDL) and increase the expression of LDL-receptors in liver 
[54]. These properties of statins suggest that they are potential agents for regulating the 
plasma levels of remnant lipoproteins as well as LDL-C. 
Atorvastatin is an HMG-CoA reductase inhibitor found to be effective in lowering fasting 
LDL-C and triglyceride levels [55]. Favorable effects of atorvastatin on postprandial 
lipoprotein metabolism have been reported in healthy normolipidemic human subjects [56-
58]. Recently, atorvastatin and rozuvastatin are reported to decrease small dense LDL-C 
significantly, which is highly correlated with remnant lipoproteins in plasma, possibly as a 
precursor of sdLDL (59). 
We investigated whether RLP bound to LDL receptor more efficiently than LDL itself via 
apoE-ligand which is rich in RLP (6). RLP competed more efficiently with ǃ-VLDL than LDL 
in LDL receptor transfected cells (to be published in Clin Chim Acta 2012 by Takahashi et 
al). These results suggested that RLP which is mainly apoE-rich VLDL more efficiently 
binds and internalizes into LDL receptor transfected cells than LDL. Similar results were 
observed in VLDL receptor transfected cells, although VLDL receptor is not present in liver 
(60). Takahashi et al found that pitabastatin (NK-104) induced VLDL receptor in skeletal 
muscle cells with significantly higher concentration (more than 10 folds) compared to 
HepG2, in which NK-104 enabled to induce LDL receptor. 
In FH of a LDL receptor deficiency, statins have a dual mechanism of action involving an 
increase in the catabolism of LDL via up-regulation of LDL-receptors and a decrease in the 
hepatic secretion of apolipoprotein (apo) B-100. The net effect is a decrease in the 
concentration of apoB-containing lipoproteins. As CM remnants are also apo E-rich and 
mainly cleared via the LDL-receptor [61, 62], an increase in receptor activity and reduced 
competition from apoB-100-containing lipoproteins was hypothesized to increase the 
removal rate of remnant lipoproteins from circulation. A recent study investigating the 
effects of high-dose, long-term statin treatment on the metabolism of postprandial 
lipoproteins in heterozygous FH, reported a decrease in the fasting and postprandial RLP-C 
as well as LDL-C [63]. Statins can induce LDL receptor in heterozygous FH which enhance 
the removal of RLP and LDL simultaneously.  
However, it has not been known which, RLP or LDL, is removed earlier or primarily from 
plasma by increased LDL receptor with statin treatment. Takahashi et al suggested the 
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possibility that remnant lipoproteins are removed more primarily from plasma by statins 
and prevent cardiovascular disease, while LDL are more likely reduced as a consequence of 
reduction of the precursor lipoproteins (to be published in Clin Chim Acta 2012 by 
Takahashi et al). 
Moreover, VLDL receptor which does not affect the removal of remnant lipoproteins in liver 
may affect on rhabdomyolysis in skeletal muscle cells, in case when VLDL receptors are 
significantly induced by statins in those cells. When plasma concentration of statins 
increased abnormally high, VLDL receptor could be induced in the skeletal muscle cells. 
Then, RLP binds and internalizes into skeletal muscle cells with significantly increased 
concentration and may cause the rhabdomyolysis in skeletal muscle cells by the cytotoxic 
effect of remnant lipoproteins (6, 64, 65). 
The direct comparison between LDL and RLP has shown that RLP with its apoE-rich ligand 
has superior binding and internalization reactivity to LDL receptor than LDL in liver, which 
is a similar reactivity with VLDL receptor. These results suggest that RLP may be more 
primarily and efficiently metabolized in liver than LDL through increased LDL receptor 
when treated with statins.  
5. Possible molecular mechanism of remnant lipoproteins associated with 
coronary artery vasospasm 
Followings are the hypothesis of molecular mechanism on the initiation and progression of 
atherosclerosis associated with fatal cardiovascular events we have proposed from our 
studies on sudden cardiac death during last two decades (Figure 2). 
Elevated plasma RLP first cause the initiation of vascular dysfunction at endothelial cell and 
smooth muscle cells through LOX-1 receptor and activate Rho-kinase pathway in vascular 
smooth muscle cells to induce coronary artery spasm as vascular smooth muscle 
hyperconstriction. However, LDL has no such biological properties to initiate the vascular 
dysfunction. Although Ox-LDL, derived from LDL modified, has very similar biological 
properties with remnant lipoproteins, the plasma concentration of Ox-LDL is significantly 
low and can not influence to the following phenomenon like remnant lipoproteins shown by 
in vitro studies (6). 
5.1 Remnant lipoproteins and impaired endothelialium-dependent vasorelaxation 
Endothelial activation or dysfunction is known to be an early event in the development of 
atherosclerosis which is not necessarily associated with strong morphological changes. 
Kugiyama et al (66) and Inoue et al (67) first found that plasma RLP-C levels, but not LDL-C 
levels, showed significant and independent correlation with impaired endothelial function 
reflected as impaired endothelium-dependent vasomotor function (vasorelaxation) in large 
and resistance coronary arteries in humans. These observations indicated the possibility that 
high plasma concentration of remnant lipoproteins impair endothelial cell function in 
human coronary arteries. 
Flow-mediated vasodilation (FMD) of the brachial artery during reactive hyperemia has 
been used as a noninvasive method to assess endothelial function. Kugiyama et al (68) and 
Funada et al (69) examined FMD by high resolution ultrasound technique before and at the  
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Fig. 2. Effect of RLP and Ox-LDL on athegenesis. The endothelial cell dysfunction is initiated 
by RLP in plasma followed by the induction of LOX-1 receptor and the associated pathway 
of various cytokines and enzymes.  Ox-LDL promotes the progression of atherosclerosis in 
subendothelial space after a large efflux of LDL from plasma and form atherosclerotic 
plaques. 
end of a 4 week treatment with oral administration of alpha-tocopherol acetate (300 
IU/day). Alpha-tocopherol improved the impairment of endothelium-dependent 
vasodilation in patients with high RLP-C, but not in patients with low RLP-C. Similarly, 
RLP and their extracted lipids impaired endothelium-dependent vasorelaxation (EDR) of 
isolated rabbit aorta at the same concentration of serum RLP-C as found in patients with 
coronary artery disease (70). In contrast, non-RLP in the VLDL fraction had no effect on 
EDR. This in vitro study further showed that co-incubation of N-acetylcysteine and reduced 
glutathione (GSH), antioxidants, that were added to incubation mixture in isolated rabbit 
aorta containing RLP, almost completely reversed the impaired EDR, suggesting that 
reactive oxygen species contained in RLP or those generated by RLP played a significant 
role in the impairment of EDR. Further, Doi et al (51) showed that RLP isolated from 
patients undergoing treatment with alpha-tocopherol lost their inhibitory action on 
vasorelaxation of isolated rabbit aorta in response to Ach, whereas RLP from patients 
receiving placebo had inhibitory action on vasorelaxation. These results suggested that high 
RLP-C level being oxidized in plasma increased the oxidative stress and contribute to 
endothelial vasomotor dysfunction in patients with high plasma concentration of RLP-C. 
Ohara et al (17) reported that remnant lipoproteins isolated from SCD cases suppressed 
nitric oxide (NO) synthetase activity and attenuate endothelium-dependent vasorelaxation. 
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Probucol is known to inhibit the oxidative modification of LDL (71), lowering serum 
cholesterol levels. Ox-LDL has been shown to impair endothelium-dependent 
vasorelaxation and antioxidants, including probucol, suppressing the impaired EDR (72) as 
RLP described above.  
5.2 Both Ox-LDL and remnant lipoproteins activate LOX-1 receptor in endothelial cells 
A scavenger receptor independent pathway for acetyl LDL and oxidized LDL in cultured 
endothelial cells, has long been known; however, it has been difficult to isolate. Recently, 
Sawamura and his colleagues (73-76) discovered and characterized lectin-like oxidized LDL 
receptor-1 (LOX-1) as a vascular endothelial receptor for Ox-LDL. Endothelial dysfunction 
or activation invoked by oxidatively modified LDL has been implicated in the pathogenesis 
of atherosclerosis by enhanced intimal thickening and lipid deposition in the arteries. Ox-
LDL and its lipid constituents, mainly composed of oxidized products of phospholipids 
such as lysophosphatidylcholine, impair endothelial production of NO, and induce the 
endothelial expression of leukocyte adhesion molecules and smooth muscle growth factors, 
which can contribute to atherogenesis via LOX-1 receptor. Vascular endothelial cells in 
culture and in vivo internalize and degrade Ox-LDL through a putative receptor-mediated 
pathway that does not involve macrophage scavenger receptor. The treatment of HUVECs 
with RLP increased LOX-1 expression in a dose dependent manner (Figure 3) and was 
completely inhibited by LOX-1- antisense, but not by LOX-1-sence. Monoclonal antibody to 
LOX-1 reported by Shin et al (77) and antisence LOX-1 oligodeoxynucleotide reported by 
Park et al (78) significantly reduced RLP-mediated production of superoxide (NADPH 
oxidase dependent), TNF-alpha, and interleukin-beta, NF-κB activation, DNA fragmentation 
(cell death: apoptosis). Further Shin et al (77) have emphasized the importance of RLP in 
increasing the expression of LOX-1 receptor protein in NADPH oxidase dependent 
superoxide production; the expression of adhesion molecules such as ICAM-1, VCAM -1 
and MCP-1 stimulated by RLP is dependent on the activation of LOX-1 receptors. These 
findings strongly suggest that LOX-1 may play the role of a receptor of RLP as well as Ox-
LDL in endothelial cells. Endothelial cell injury caused by RLP via LOX-1 receptor activation 
evidently can initiate atherosclerosis. Cilostazol, a platelet aggregation inhibitor and 
vasodilator (79), is known to reduce plasma RLP-C levels in patients with peripheral artery 
disease (80) and has showed significant protective effect against RLP-induced endothelial 
dysfunction by suppressing these variables both in-vitro and in-vivo with its antioxidative 
activity (81). 
5.3 Remnant lipoproteins activate LOX-1 receptor in smooth muscle cell 
Coronary vasospasm has been considered to occur at vascular smooth muscle cells (VSMCs) 
and the migration of VSMCs from media to intima and subsequent proliferation play key 
roles in atherogenesis. A previous report has demonstrated that RLPs induce VSMC 
proliferation [82]; however, receptors for RLPs in VSMCs have not yet been well 
characterized until recently reported by Aramaki et al (83), although LRP in the liver, apoB- 
48-R in macrophages, and VLDL receptor in heart, skeletal muscle, adipose tissue, brain and 
macrophages [84, 85] have been shown to act as a receptor for RLPs. LOX-1 expression is 
dynamically inducible by various proatherogenic stimuli, including tumor necrosis factor-
ǂ(TNF-ǂ), heparin-binding epidermal growth factor-like growth factor (HB-EGF), and Ox- 
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Fig. 3. RLPs, but not nascent VLDL (n-VLDL), induce LOX-1 expression in BVSMCs. (A ) 
After BVSMCs were treated with the indicated concentrations of RLPs for 16 h, total cell 
lysates were subjected to immunoblotting for LOX-1. TNF-ǂ served as a positive control. (B) 
After treatment with 25μg/ml of RLPs for the indicated time periods, total cellular RNA 
was subjected to Northern blot analyses. Bands for 28S and 18S ribosomal RNAs were 
visualized by ethidium bromide staining to control the amount of RNA loaded.  (*) p < 0.001 
vs. 0g/ml of RLPs,  (#) p < 0.05 vs. 0 h incubation (cited from Ref 83). 
A 
B 
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LDL. Furthermore, LOX-1 is highly expressed by macrophages and VSMCs accumulate in 
the intima of advanced atherosclerotic lesions, as well as endothelial cells covering early 
atherosclerotic lesions in vivo, indicating that LOX-1 appears to play important roles at 
various stages of atherogenesis.. Aramaki et al (83) recently provided direct evidence, by 
cDNA and short interference RNAs (siRNAs) transfection, that LOX-1 acts as a receptor for 
RLP (Figure 1) and whereby induce VSMC migration, depending upon HB-EGF shedding 
and the downstream signal transduction cascades. The direct evidences that LOX-1 serves as 
a receptor for RLPs in vascular smooth muscle cells (VSMCs) were shown by use of two cell 
lines which stably express human or bovine LOX-1 and siRNA directed to LOX-1. In 
addition, involvement of metalloproteinase activation, HB-EGF shedding, EGFR 
transactivation, and activation of ERK, p38 MAPK and PI3K were also observed in RLP 
induced migration of BVSMCs. Competition studies in cells stably expressing LOX-1 
indicated binding site(s) on the LOX-1 molecule for RLPs and oxidized LDL appear to be 
identical or overlapped, suggesting the C-terminal cysteine-rich C-type lectin-like domain 
was shown to be the responsible binding site(s) for RLPs [86]. These studies suggested the 
importance of LOX-1 in RLP-induced atherogenesis, as well as that induced by oxidized 
LDL. RLPs induced cell migration and LOX-1 expression by RLP-LOX-1 interactions, thus 
making a positive-feed back loop to further enhance the RLP-induced vascular dysfunction, 
as already showed in oxidized LDL-induced vascular dysfunction. In accordance with a 
previous report [77, 78], RLP-induced LOX-1 expression and cell migration depend upon 
HB-EGF shedding and subsequent EGFR transactivation demonstrated. Furthermore, the 
involvement of ERK, p38 MAPK and Akt as signal transducrion cascades located 
downstream to the EGFR transactivation were shown. JNK was not activated by RLPs or not 
involved in RLP-induced LOX-1 expression or cell migration (84). 
These results suggested that RLP induced LOX-1 expression and enhance the activation of 
smooth muscle cells. 
5.4 Remnant lipoproteins activate Rho-kinase in smooth muscle cells and induce 
vasospasm 
Coronary vasospasm has been postulated to play an important role in SCD, although a direct 
demonstration for the hypothesis is still lacking. Shimokawa and his colleagues demonstrated 
the close relation between RLP and coronary vasospasm that is mediated by upregulated Rho-
kinase pathway (18). The expression and the activity of Rho-kinase are enhanced at the 
inflammatory coronary lesions in the porcine model with interleukin-1 (19, 88).  
RLP isolated from the plasma of SCD cases exert a potent upregulating effect on Rho-kinase 
in hcVSMC (18). In organ chamber experiments, serotonin caused hyperconstriction of 
vascular smooth muscle cells (VSMC) from RLP-treated segment, which was significantly 
inhibited by hydoxyfasudil (a selective Rho-kinase inhibitor). In cultured human coronary 
VSMC, the treatment with RLP significantly enhanced the expression and the activity of 
Rho-kinase. These results indicated that RLP isolated from the plasma of sudden cardiac 
death cases upregulated Rho-kinase in coronary VSMC (promoted inflammation) and 
markedly enhanced coronary vasospasmic activity.  
Further, Oi et al (18) performed in vivo study on the formation of coronary vascular lesion 
by RLP, using healthy pigs in which they treated pig coronary arteries with RLP (an 
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equivalent concentration of plasma RLP) isolated from the plasma of SCD cases. After 1 
week, intracoronary serotonin caused hyperconstriction in the segment treated with RLP 
but not in the non-RLP VLDL treated segment (Figure 4). Likewise, RLP treated with 
hydroxyfasudil, a selective Rho-kinase inhibitor, dose dependently inhibited the coronary 
spasm in pigs. 
 
Fig. 4. RLP ( RLP in VLDL fraction; RLP-VLDL) from patients with SCD markedly enhance 
coronary vasospastic activity in pigs. Coronary angiograms before (A) and after 
intracoronary serotonin (B). Black arrows indicate RLP site at coronary artery; white arrows, 
non-RLP site. RLP induced significant hyperconstriction at treated coronary site after 1 
week, while hydroxyfasudil completely inhibited serotonin (5HT)-induced coronary 
hyperconstriction at RLP site (cited from Ref 18). These results were explained by the 
induction of Rho-kinase ǂ and Rho-kinase ǃ, of which mRNA expression was enhanced by 
the treatment with RLP but not that with non-RLP.  
It has been recently reported that sphingosine 1-phosphate (S1P) and 
sphingosylphosphorylcholine, present in serum lipoproteins, behave as a lipid mediator and 
cause vasoconstriction through upregulation of Rho/Rho-kinase pathway (89). The possible 
role of S1P and sphingosylphosphorylcholine in the RLP fraction remains to be elucidated. 
These results suggested the importance of intervention to suppress the cardiovascular 
events more aggressively by such as inhibiting Rho-kinase activation than to slow down the 
progression of atherosclerosis. 
6. Conclusion remarks 
Sudden and unexplained cardiac death has been known for many years in Southeast Asian 
countries, including Japan. These deaths were named differently in each country such as 
Pokkuri Death Syndrome in Japan, “Lai Tai” in Thailand, “Bangungut “ in the Philippines, 
“Dream Disease” in Hawaii, and “Sudden Unexpected Nocturnal Death Syndrome” among 
South Asian immigrants in the USA. However, the clinical and pathological features of these 
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sudden death cases are surprisingly similar with no coronary atherosclerosis and mainly 
occur among young males during sleep in the midnight, together with an excessive food 
and alcohol intake. 
We have proposed a hypothesis that could explain a possible cause of PDS based on the 
postprandial increase of remnant lipoproteins in plasma and narrowed circumferences of 
coronary arteries in PDS cases. The elevated plasma RLP initiates the vascular dysfunction at 
endothelial cells in narrowed coronary arteries as an early event in the development of 
atherosclerosis and induces severe coronary spasm under stress or genetic disorder, possibly 
for example, through activating LOX-1 receptor and Rho-kinase pathway, at smooth muscle 
cells to cause cardiac arrest. LDL or low concentration of Ox-LDL could not explain these 
phenomena as RLP. Taken together, we have proposed that the severity of coronary 
atherosclerosis and the occurrence of cardiovascular events in CHD cases could be considered 
as separate factors, judging from the physiological role of LDL and RLP in plasma. Therefore, 
the intervention should be more targeted to suppress the plasma remnant lipoproteins to 
prevent cardiovascular events more aggressively rather than to slow down the progression of 
atherosclerosis by LDL. 
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